AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01695369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A; Comfilcon A
Description: Senofilcon A; Comfilcon A
Study NCT01695369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A; Comfilcon A
Description: Senofilcon A; Comfilcon A
Study NCT01695369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A; Senofilcon A
Description: Comfilcon A; Senofilcon A
Study NCT01695369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A; Senofilcon A
Description: Comfilcon A; Senofilcon A
Study NCT00955110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: 15mg or 30mg
Study NCT00955110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: 30mg or 60mg
Study NCT00955110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a sugar pill.
Study NCT00955110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 8 mg
Study NCT00955110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 8 mg
Study NCT00955110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: 8 mg
Study NCT02040246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
Study NCT02040246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
Study NCT03120910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse CO-Oximeter Sensor
Description: Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
Study NCT00639067 — intervention group
Intervention type: DEVICE
Intervention: Breath Collection Apparatus
Description: Breath collected and analyzed for markers of lung cancer.
Study NCT00003270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: IV
Study NCT00003270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: IV
Study NCT00003270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: IV
Study NCT00003270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV
Study NCT00003270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: IV
Study NCT00003270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: IV
Study NCT00003270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: IV
Study NCT00003270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: IV
Study NCT00003270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: High energy X-rays
Study NCT04415138 — intervention group
Intervention type: DEVICE
Intervention: Robotic-assisted mitral valve repair
Description: Mitral valve repair using robotic technology (DaVinci X platform)
Study NCT00609271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low carbohydrate diet
Description: \<40 grams carbohydrate/day
Study NCT00609271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low fat diet
Description: \<30% fat, \<7% saturated fat
Study NCT02551640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeatForward App (on study smartphone)
Description: The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group.
Study NCT03396939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthosis
Description: All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
Study NCT02947945 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reslizumab
Description: All subjects will receive Reslizumab
Study NCT00582387 — intervention group
Intervention type: GENETIC
Intervention: specimen samples
Description: blood, urine and tissue
Study NCT00582387 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Study NCT03195595 — intervention group
Intervention type: DEVICE
Intervention: mitral valve replacement
Description: early postoperative outcome regarding pain in minimal invasive technique
Study NCT03195595 — intervention group
Intervention type: DEVICE
Intervention: conventional mitral valve replacement
Description: early postoperative outcome regarding pain in conventional median sternotomy
Study NCT01839994 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CF-CRT combined with BT or SBRT boost.
Description: CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
Study NCT04366960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin
Study NCT01679327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01679327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Study NCT01839994 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CF-CRT alone
Description: Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
Study NCT01839994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal treatment (neoadjuvant androgen deprivation)
Description: Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
Study NCT01839994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal treatment (neoadjuvant androgen deprivation)
Description: Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
Study NCT02864875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Receive fibrinogen concentrate 50mg/kg of body weight after randomization
Study NCT03945331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulator
Description: DS8R Electrical Stimulator For Human Research
Study NCT01679327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate (CF)
Study NCT01679327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study NCT01679327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT05488158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulation
Description: Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
Study NCT03945331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural spinal cord stimulation system
Description: Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
Study NCT02062177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
Study NCT02062177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged \< 70, 0.03 mg/Kg if aged > 70.
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg iv over 30 minutes day 1
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg iv over 30 minutes day 1
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 165 mg/sqm iv over 60 minutes day 1
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/sqm iv over 60 minutes day 1
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours day 1
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours day 1
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 3200 mg/sqm 48 h-continuous infusion
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 3200 mg/sqm 48 h-continuous infusion
Study NCT03721653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
Study NCT04037722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 45 g whey + 20 g maltodextrin
Study NCT04037722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-OHB + Whey
Description: 50 g ketone + 45 g whey + 20 g maltodextrin
Study NCT00081653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 3 years
Study NCT00081653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate [Bonviva/Boniva]
Description: 100mg po monthly for 3 years
Study NCT04516915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 twice daily at 22.5mg doses for 14 days
Study NCT04516915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir twice daily at 75mg doses for 14 days
Study NCT04516915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir twice daily at 75mg doses for 14 days
Study NCT04432753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening Decision Aid with Incidental Findings Information
Description: The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
Study NCT04432753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lung Cancer Screening Decision Aid without Incidental Findings Information
Description: The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
Study NCT03013530 — intervention group
Intervention type: PROCEDURE
Intervention: Decision making for ICU patients' care
Description: Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
Study NCT04651036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0605
Description: a pegfilgrastim biosimilar to US Neulasta.
Study NCT04651036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US Neulasta
Description: US Neulasta
Study NCT00470691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plaster cast
Description: complete circular plaster cast
Study NCT00470691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dorsal splint
Description: dorsal plaster splint
Study NCT04067583 — intervention group
Intervention type: OTHER
Intervention: Physician questionnaire
Description: This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
Study NCT03310320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0284 oral solution 2.5 mg/mL
Description: AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
Study NCT03310320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AZD0284 oral solution, twice daily for 4 weeks
Study NCT03198039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Isha Kriya (IK) meditation approximately 12 minutes, twice a day
Study NCT00669162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20mg/m2 IV weekly for 7 weeks
Study NCT00669162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
Study NCT00669162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex and Zoladex (or Lupron)
Description: Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
Study NCT03168503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LGG+Promitor™
Description: synbiotic
Study NCT03168503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Promitor™
Description: Soluble Corn Fiber
Study NCT02726867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
Study NCT02726867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lacosamide
Description: Treatment will consist of LCM 600 mg i.v. over 10 minutes
Study NCT03168503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LGG-PB12+Promitor™
Description: synbiotic
Study NCT03168503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Control
Study NCT01161420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspire Upper Airway Stimulation System
Description: Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
Study NCT03123315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral Illuminating Catheter
Description: This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
Study NCT04006782 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narrow dental implants
Description: Insertion of narrow dental implants in multiple fixed prosthesis
Study NCT04290390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Segesterone Acetate and Ethinyl Estradiol
Description: Contraceptive Vaginal System
Study NCT03552484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visit Program
Description: Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care
Study NCT03552484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care/Online Survey
Description: Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
Study NCT04169815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access Immunodiagnostic Products
Description: Access Natriuretic Peptide Assay
Study NCT02496104 — intervention group
Intervention type: BEHAVIORAL
Intervention: Package n°1 of the APIB
Study NCT02726867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Treatment will consist of KET 2.5 mg/kg over 10 minutes
Study NCT02726867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
Study NCT02725255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ujiplus
Description: Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
Study NCT02725255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: 400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
Study NCT02725255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: uji
Description: maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
Study NCT02021968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV-TV003
Description: TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10\^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02021968 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rDEN2∆30-7169
Description: The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02021968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2∆30-7169
Description: The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02021968 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT04290390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: CYP3A inducer
Study NCT04290390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: CYP3A inhibitor
Study NCT00626054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG solution in a single dose of 3 liters
Description: Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
Study NCT00626054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG solution
Description: PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test